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Abstract
Recent evidence supports a role for microRNAs (miRNAs) in regulating the life span of model organisms. However, little is
known about how these small RNAs contribute to human aging. Here, we profiled the expression of over 800 miRNAs in
peripheral blood mononuclear cells from young and old individuals by real-time RT-PCR analysis. This genome-wide
assessment of miRNA expression revealed that the majority of miRNAs studied decreased in abundance with age. We
identified nine miRNAs (miR-103, miR-107, miR-128, miR-130a, miR-155, miR-24, miR-221, miR-496, miR-1538) that were
significantly lower in older individuals. Among them, five have been implicated in cancer pathogenesis. Predicted targets of
several of these miRNAs, including PI3 kinase (PI3K), c-Kit and H2AX, were found to be elevated with advancing age,
supporting a possible role for them in the aging process. Furthermore, we found that decreasing the levels of miR-221 was
sufficient to cause a corresponding increase in the expression of the predicted target, PI3K. Taken together, these findings
demonstrate that changes in miRNA expression occur with human aging and suggest that miRNAs and their predicted
targets have the potential to be diagnostic indicators of age or age-related diseases.
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Introduction
Human aging is a highly complex process that is characterized
by an increase in age-associated diseases such as cancer, type 2
diabetes mellitus, autoimmunity, infections, cerebrovascular and
cardiovascular disease. Important in the study of aging is the
discovery of new biomarkers that serve as indicators of tissue age
and development and that also can aid in the diagnosis of age-
related diseases. Studies in model systems suggest that longevity
can be modulated by changes in gene and protein expression. In
addition, it is widely believed that factors such as calorie restriction
may extend the lifespan of organisms, in part, by modulating the
levels and expression of particular genes and pathways [1,2].
Recent evidence suggests that microRNAs (miRNAs) are key
regulators of gene expression. miRNAs are small non-coding
(,22 nt) RNAs that incorporate into the miRNA-induced
silencing complex (RISC) [3]. This complex typically negatively
regulates gene expression through mRNA degradation, translation
inhibition or by performing both functions [4,5]. Accumulating
data suggest that miRNAs are important regulators of a variety of
cellular processes including cell proliferation, survival, differenti-
ation and replicative sensescence [6,7].
Extensive research in Caenorhabditis elegans has uncovered a role
for miRNAs in controlling lifespan [8]. For example, reducing the
activity of the C. elegans miRNA, lin-4, shortens lifespan.
Conversely, increasing the activity of lin-4 lengthens lifespan [9].
Further evidence implicating lin-4 in modulating lifespan includes
experiments showing that lin-4 affects lifespan in part through
repression of its target lin-14. In addition, lin-14 has an opposite
effect on lifespan when compared to lin-4 [9]. More recently, a
genome-wide transcriptional profile of miRNAs in C. elegans
showed that the expression of approximately one third of the
miRNAs is modulated during the lifespan [10]. Furthermore, the
majority of these age-regulated miRNAs were found to be
downregulated in older animals. In addition to C. elegans, changes
in miRNA expression occur with aging in the mouse liver and
brain [7,11,12,13]. Most recently, differences in microRNA
abundance were observed in the liver from the Ames dwarf
mouse, which have extended longevity compared to wild-type
mice [7,11,12]. These data suggest that miRNA expression
patterns change with the lifespan of model organisms and indicate
that different levels of miRNAs may directly affect the aging
process.
Recent studies have suggested that changes in miRNA
expression also occur with human cellular senescence, an in vitro
model system that recapitulates certain aspects of aging and cancer
[14,15]. Using two different human cells lines, Brosh and
colleagues reported that the onset of cellular senescence, defined
as an irreversible decline in cell proliferation after a finite number
of divisions in culture, significantly decreases miRNA expression
[16]. Furthermore, modulation of two groups of miRNAs has been
shown to affect senescence in vitro. These include miR-106b, miR-
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These subsets of miRNAs and others appear to target different
senescence-associated genes, including several that encode cell
cycle proteins (the miR-106b group), MKK4 (miR-15b, miR-24,
miR-25, miR-141), p16
INK4a (miR-24), and IL-6/IL-8 (miR-
146a/b) [16,17,18,19]. Importantly, several of these target genes
have been shown to be elevated in human tissues from older
individuals, suggesting that changes in miRNA expression may
modulate key targets to drive senescence.
Research in this area has largely focused on dissecting miRNAs
that are important for age-related diseases such as cancer. Little is
known about the role of miRNAs in mammalian aging. Here, we
have profiled miRNAs expressed in both young and old
individuals and identified those that are differentially expressed
in older individuals. Furthermore, we report that several putative
targets of miRNAs including, PI3K, H2AX and c-Kit are
upregulated with age in humans. Thus, changes in the expression
of miRNAs and their predicted targets occur with the aging
process, and may serve as potential biomarkers of susceptibility to
age-associated diseases.
Results
Changes in miRNA expression in young versus old
individuals
To examine whether miRNA expression is altered with age in a
human population, we obtained peripheral blood mononuclear
cells (PBMCs) from young (30 year old) individuals and old (64
year old) individuals. Demographic data for these subjects are
presented in Table 1A. We employed the miRNome miRNA
profiler assay, that uses real-time RT-PCR to screen over 800
human miRNAs, in 2 different sets of young and old participants
(miRNome 1 and miRNome 2) (Table 1A). Interestingly, we found
that most miRNAs are downregulated in older participants
compared to younger participants, which is consistent with
microarray data from both C. elegans and senescent cells in vitro
(Fig. 1)[10,16].
We then compared the differentially regulated miRNAs that we
found in our two different miRNome experiments. Of the 128 and
73 miRNAs found to be upregulated 2-fold in older patients in
miRNome 1 and miRNome 2, 21 overlapped between the data
sets (Fig. 2, Table S2). 256 and 437 miRNAs were at least 2-fold
lower in miRNome 1 and 2, respectively. Of these miRNAs 144
were found to overlap between datasets, indicating that in PMBCs
approximately 16.5% of miRNAs studied were reduced by 2-fold
with age (Fig. 2, Table S2).
Downregulation of miRNAs with human age
To determine whether the changes in miRNA expression
observed with age are consistent in a larger number of individuals,
we validated the levels of a number of miRNAs in 14 young and
14 old participants (see Table 1B for demographics). The most
upregulated and downregulated miRNAs within our miRNome
analysis and other aging-associated miRNAs were chosen for
further analysis. Out of the 32 miRNAs tested, 9 were significantly
downregulated in older participants (Fig. 3A). The levels of several
miRNAs were not significantly changed when we analyzed them
in this larger group (Fig. S1). In general, the miRNA expression
patterns in the individuals we examined by miRNome analysis
showed similar magnitudes of change when we examined them
along with the larger cohort. However, two miRNAs (miR-496,
miR-1538) were found to be upregulated in the old participants by
miRNome analysis and in the validation experiments, but when
examined among the larger cohort these miRNAs were found to
be downregulated in older participants (Fig. 3A, Table S1, S3).
Furthermore, downregulation of miR-24 and miR-221 (two
miRNAs we examine further below) was also observed when we
measured their expression using a TaqMan microRNA assay
(Fig. 3B).
To address whether the changes in miRNA expression may be
due to age-dependent differences in subsets of lymphocytes, we
examined different T cell markers, which represent a population of
lymphocytes that undergo some age-dependent changes
[20,21,22,23]. Consistent with published reports for our age
groups, we did not find any significant changes in the CD4, CD8,
CD4/CD8 ratio or IL-7 receptor expression between young and
old participants in our cohort (Fig. S2) [20,21,22,23]. Taken
together, these observations and the fact that we observe
significant changes in miRNA expression suggest that the changes
in miRNA expression are unlikely to be due to the modest effects
observed in different lymphocyte subsets in our age groups.
Target and pathway analysis of age-associated miRNAs
Each miRNA can regulate numerous target genes and therefore
has the potential to modulate multiple pathways. To explore what
targets and pathways may be regulated by these age-associated
miRNAs, we used the Target Scan Human 5.1 database to predict
targets for each miRNA that we identified in this study.
Surprisingly, Target Scan did not predict any targets for miR-
1538 nor are there any published reports on this miRNA.
Therefore, we excluded this miRNA from any further examina-
tion. Two members of the miR-103 gene family, miR-103 and
miR-107, are both downregulated with age. miR-103 and miR-
107 only differ by one nucleotide and are predicted to target the
same genes. Thus, these miRNAs were combined in our
subsequent analysis.
The predicted targets for each age-associated miRNA from
Target Scan were used for Ingenuity Pathway Analysis (IPA) to
reveal the diseases, molecular functions, physiological systems and
canonical pathways associated with each miRNA (Table 2). This
analysis identified cancer as the most common disease among
these miRNAs, which is not unexpected, as the most potent risk
factor for cancer is advancing age. Cardiovascular disease was also
another prominent disease. The targets for the age-associated
miRNAs were most prominently predicted to function in gene
Table 1. Patient demographic information.
(A) miRNome Young Old
n2 2
Age 30 64.5
Race W W
Sex M M
(B) Validation Young Old
n1 41 4
Age 30.160.3 64.260.4
Race 8 W, 6 AA 8 W, 6 AA
Sex 8 F, 6 M 8 F, 6 M
Race and Sex 5 W-F, 3 AA-F 5 W-F, 3 AA-F
3 W-M, 3 AA-M 3 W-M, 3 AA-M
Demographics for individuals in this sub-cohort of the HANDLS study. Age is
reported as the mean 6 SD. Abbreviations are as follows: W, White; AA, African
American; F, Female; M, Male.
doi:10.1371/journal.pone.0010724.t001
microRNA Expression with Age
PLoS ONE | www.plosone.org 2 May 2010 | Volume 5 | Issue 5 | e10724Figure 1. Downregulation of miRNA expression in old individuals. For each panel, one young 30- year-old participant and one old 64-year-
old participant were screened for miRNA expression using a real-time RT-PCR based miRNome miRNA profiler kit as described in Materials and
Methods. Different pairs of individuals were used for both miRNome 1 and miRNome 2. The heat map was generated using dChip software and
indicates the fold log10 relative change in expression in young versus old participants[49]. The top upregulated and downregulated miRNAs are
shown. Blue indicates downregulation of miRNA expression in the old individuals and red indicates upregulation of miRNA expression in the old
individuals. Each patient was sex and race matched as indicated in Table 1. A detailed spreadsheet of the data is available as supplementary
information (Table S1). * next to the microRNA refers to the minor form of the miRNA.
doi:10.1371/journal.pone.0010724.g001
microRNA Expression with Age
PLoS ONE | www.plosone.org 3 May 2010 | Volume 5 | Issue 5 | e10724expression. However, very little overlap was observed between the
molecular functions and pathways for these miRNAs, suggesting
that these miRNAs may regulate multiple pathways that influence
diseases, such as cancer.
Given the fact that IPA revealed that cancer was the most
prominent disease linking these age-associated miRNAs and that 5
out of the 9 age-associated miRNAs have been previously reported
to play a role in various cancers (Fig. 3C), we initially focused on
these age-associated miRNAs with oncogenic (oncomirs) or tumor
suppressive (ts-mirs) functions. To gain a better understanding of
what targets may be regulated by these cancer-related miRNAs,
we compared the overlap between the predicted targets for these
miRNAs. Consistent with the variability in overlapping molecular
pathways in our IPA, there was little overlap between the
predicted targets among the age-associated oncomirs/ts-mirs
(Fig. 4A). However, two predicted targets were in common
between the miRNAs, PIK3R1 Phosphoinositide-3 kinase,
regulatory subunit 1 alpha, and NOVA1 Neuro-oncological
ventral antigen 1. NOVA1 is a brain-specific protein. We chose
to focus our further investigations on PIK3R1 which encodes the
Figure 2. Upregulated and downregulated miRNAs in young and old individuals. A Venn diagram showing miRNAs that expression was
either upregulated .2-fold (A) or downregulated .2-fold (B) in the old participants compared to young participants from the two different
miRNome analyses in Figure 1. Listed are the miRNAs that overlapped between these 2 different data sets. The complete miRNome analysis for the
listed miRNAs is available (Table S2).
doi:10.1371/journal.pone.0010724.g002
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kinase that plays a key role in many cellular processes including
cell survival, cell proliferation, and tumorigenesis [24,25].
Upregulation of PI3 Kinase expression with age
We examined whether the expression of PI3K may be altered in
young and old participants, consistent with the expression of the
Figure 3. Real-time RT-PCR validation of changes in miRNA expression in young and old participants. (A) Expression of miRNAs from
the miRNome analysis were further validated in 14 young and 14 old subject PBMCs (see Table 1B for detailed demographic data) using real-time RT-
PCR as described in Materials and Methods. The histograms show normalized averages 6 SEM from duplicate experiments. *P,0.05 by both
Student’s t-test and three-way ANOVA. (B) miR-24 and miR-221 expression was examined in 14 young and 14 old individuals using a TaqMan
microarray assay as described in Materials and Methods. (C)Age-associated miRNAs that have been implicated in various cancers. See recent reviews
for details [4,35,50].
doi:10.1371/journal.pone.0010724.g003
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most cases miRNAs downregulate the expression of their target
genes by inducing cleavage and degradation of mRNAs or by
inhibiting protein translation [4,5], and we observed downregu-
lation of these cancer-related miRNAs in older individuals, we
hypothesized that the levels of PI3K would be elevated in older
participants. Indeed, we found by real-time RT-PCR that mRNA
levels of the p85a subunit of PI3K were significantly higher in
older participants than younger participants (Fig. 4B). Immuno-
blotting experiments confirmed that p85a protein levels were
elevated in older individuals (Fig. 4B, 4C), suggesting that age-
associated miRNAs may affect p85a by modulating both p85a
mRNA stability and translation. In addition to the p85a regulatory
subunit, PIK3R1 also encodes its splice variants p55a and p50a,
which lack the N-terminal SH3 and BCR homology domains [24].
Using primers specific for these isoforms, we did not observe any
significant changes in expression of p55a or p50a mRNA in old
participants (data not shown). In addition, p55a and p50a proteins
were expressed at low levels in PBMCs from these individuals and
were not significantly altered among the different age groups (data
not shown). Therefore, the age-dependent upregulation of the
regulatory subunit of Class 1A PI3K appears to be specific to the
p85a subunit and this expression correlates with downregulation
of the age-associated miRNAs.
To determine whether the age-associated miRNAs regulate
PI3K expression, we focused on miR-221 since this miRNA had
the highest prediction score in Target Scan to target p85a.W e
lowered the levels of miR-221 using an antagomir, an RNA
complementary (antisense, AS) to miR-221, to mimic the change
in expression of miR-221 with age. Transfection with (AS)miR-
221 reduced miR-221 expression, and increased both the mRNA
and protein levels of p85a (Fig. 5A,B). This suggests that miR-221
regulates the expression of p85a and that this miRNA may
modulate p85a levels during the aging process.
In order to determine whether miR-221 regulates the p85a
39UTR, we generated dual-luciferase constructs (Fig. 5C). Com-
putational algorithms predicted three different miR-221 sites in
the p85a 39 UTR (Fig. 5C,D). Therefore, we made two different
constructs that span the predicted miR-221 target sites (pLuc-p85
(2644) and pLuc-p85 (4491)) and cloned them 59 to the Renilla
luciferase (RL) reporter. The plasmid contains a second reporter,
firefly luciferase (FL), which is driven from a separate promoter
and serves as a transfection control. We measured the ratios of
RL/FL in Hela cells transfected with the different dual-luciferase
constructs and either control siRNA, precursor (Pre)miR-221, or
(AS)miR-221. Transfection of the pLuc-p85 (2644) plasmid
reduced the activity of the luciferase reporter compared to pLuc
control, indicating that either or both of the first two predicted
sites in the p85a 39 UTR are targeted by endogenous miRNAs to
repress the translation of p85a mRNA (Fig. 5E). Elevating the
levels of miR-221 using (Pre)miR-221 further reduced luciferase
activity compared to control siRNA, while reducing the levels of
miR-221 by transfection of (AS)miR-221 increased the expression
of the reporter above control (Fig. 5E). These findings suggest that
the effects observed on RL/FL activity for the pLuc-85 (2644)
plasmid depend on the presence of miR-221. Interestingly, RL/FL
Table 2. Ingenuity analysis of microRNAs significantly downregulated with age.
miR-103/107 miR-128 miR-130a miR-155
Diseases and Disorders Cardiovascular disease Genetic disorder Cancer Hematological Disease
Genetic Disorder Neurological Disease Cardiovascular disease Cancer
Molecular and Gene Expression Gene expression Cell death Gene Expression
Cellular Functions Cellular Movement Amino Acid Metabolism Cellular Movement Cellular Development
Physiological
Systems
Nervous System
Development and
Function
Organismal Development Organismal Development Organismal Development
Behavior Organ Development Organ Development Hematological System
Development and Function
Canonical Pathways Ran signaling Molecular Mechanisms
of Cancer
Pantothenate and CoA
Biosynthesis
T cell Receptor Signaling
Wnt/b-catenin Signaling PPARa/RXR Activation Human Stem Cell Pluripotency Prolactin Signaling
miR-24 miR-221 miR-496
Diseases and Disorders Cancer Connective Tissue Disorder Organismal Injury and
Abnormalities
Neurological Disease Cancer Respiratory Disease
Molecular and Amino Acid Metabolism Cellular Development Carbohydrate Metabolism
Cellular Functions Post-translational Modification Cell Cycle Small Molecule Biochemistry
Physiological
Systems
Cardiovascular System
Development and Function
Lymphoid Tissue Structure
and Development
Cell-mediated Immune Response
Connective Tissue
Development and Function
Nervous System Devel-
opment and Function
Hematological System
Development and Function
Canonical Pathways PTEN Signaling Clathrin-mediated Endocytosis Growth Hormone Signaling
Axonal Guidance Signaling ERK/MAPK Signaling Wnt/b-catenin Signaling
The predicted targets (from Targetscan) were compiled for each respective miRNA and were examined using Ingenuity software. The top two pathways for each
parameter are listed.
doi:10.1371/journal.pone.0010724.t002
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(4491) plasmid with or without the different miRNAs, indicating
that this predicted miR-221 site is not important for miRNA-
mediated translation repression of p85a mRNA (Fig. 5E).
Targets of age-associated miRNAs are differentially
expressed with age
To examine if expression of other target genes may be altered in
older participants, we focused on previously reported targets for
Figure 4. Putative target validation of miRNAs downregulated by age. (A) A Venn diagram showing the overlap between predicted targets
of cancer-related miRNAs that were found to be downregulated in older participants. All cancer-related miRNAs have in common the predicted
targets PIK3R1 and NOVA1. (B) Relative mRNA expression of PI3K, c-Kit and H2AX from 14 young and 14 old participants using real-time RT-PCR. The
histograms show the normalized means 6 SEM. (C) Representative immunoblots showing protein expression of PI3K, c-Kit and H2AX in a young and
old patient. Participant PBMCs were lysed and immunoblotted with anti-PI3K, anti-c-Kit and anti-H2AX antibodies and reprobed with anti-actin and
anti-histone H3 antibodies as protein loading controls. The same individuals were used for each representative immunoblot in C. (D) The protein
levels of PI3K, c-Kit and H2AX from PBMCs were quantified from immunoblots and normalized to the amount of actin or histone H3. The histogram
represents the normalized relative mean 6 SEM from 14 young and 14 old individuals for PI3K and 10 young and 10 old individuals for c-Kit and
H2AX. **P,0.01, *P,0.05 by Student’s t-test.
doi:10.1371/journal.pone.0010724.g004
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PLoS ONE | www.plosone.org 7 May 2010 | Volume 5 | Issue 5 | e10724Figure 5. miR-221 regulates p85 expression. (A) Hela cells were transfected with control (Ctrl) siRNA or (AS)miR-221 and 48 h later mRNA levels
of miR-221 and p85 were analyzed by RT-qPCR using U6 and UBC for normalization, respectively. The histogram represents the mean 6 SEM from
three independent experiments. *P,0.05 by Student’s t-test. (B) Forty eight hrs after transfection with the indicated small RNAs, protein lysates were
used for Western blot analysis of p85a expression. b-actin signals served as protein loading controls. (C) Schematics of the p85a 39UTR and the dual-
luciferase plasmids used in (E). pLuc control plasmid expresses both the Renilla luciferase (RL) and firefly luciferase (FL). Constructs of the p85a 39 UTR
span either two (pLuc-p85 (2644)) or one (pLuc-p85 (4491)) of the predicted miR-221 sites (black bars). (D) The p85a mRNA was predicted to be
targeted by miR-221 using prediction algorithims from Target Scan and microRNA.org. The position of each predicted site within p85a is indicated. (E)
microRNA Expression with Age
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in this study. It has been demonstrated that miR-221 regulates
expression of the oncogene c-Kit [26], a receptor tyrosine kinase
that is overexpressed and/or highly active in various leukemias
and other cancers [27,28]. We found that c-Kit protein levels were
higher in older individuals (Fig. 4B–D), but that c-Kit mRNA
levels were not changed between the different groups, consistent
with the fact that miR-221 has been reported to predominantly
regulate c-Kit translation rather than c-Kit mRNA levels [26].
miR-24 has been reported to modulate the expression of histone
H2AX [29], which is a key component in the repair of DNA
double-strand breaks. It has been reported that phosphorylation of
H2AX (referred to as c-H2AX) increases with age in human
donor PBMCs [30]. We found that H2AX expression was
significantly higher at both the mRNA and protein levels in older
participants (Figure 4B-D). This suggests that in addition to the
occurrence of c-H2AX, expression of H2AX may also be a
molecular indicator of age.
Discussion
Despite the accumulating evidence linking miRNAs to various
age-related diseases, very little is known about how these small
RNAs contribute to the aging process. Here, we have surveyed
expression of miRNAs from young and old individuals in order to
provide a genome-wide assessment of miRNA expression during
human aging. We chose to use a miRNome real-time RT-PCR
based approach instead of microarray for several reasons. In
general, real-time RT-PCR is more quantitative, accurate and
often microarray data need validation by RT-PCR. We used this
initial profiling to identify miRNAs that exhibit age-associated
changes in expression in two different sets of young and old
individuals and further validated the abundance of these miRNAs
in a larger cohort. We identified 9 miRNAs that were significantly
downregulated with age in a larger number of individuals,
suggesting that miRNAs may be important regulators of lifespan.
Interestingly, we found in our screen of over 800 human
miRNAs that the majority of miRNAs are downregulated with age
(Fig. 1,2). In comparing the two different miRNome analyses
(which represent different young and old participants) 16.5% of
the miRNAs decline in abundance, whereas 2.5% increase in
abundance 2-fold (Fig. 2). These findings are comparable to prior
microarray studies where the majority of miRNAs decline in
abundance over the lifespan of C. elegans [10]. Given this similarity
and the fact that many of the human miRNAs are evolutionarily
conserved, miRNAs may serve as key regulators of age-related
decline across species. Nonetheless, it is important to study
miRNAs in the context of human aging. In agreement with the
increased complexity of higher organisms, currently there are
approximately 6X more miRNAs in humans than in worms (,851
versus ,136)(MicroCosm Targets).
In addition to C. elegans, changes in miRNA expression have
been observed with aging in the mouse. Specifically, in the mouse
brain 31 miRNAs are significantly upregulated and 17 are
downregulated with age. The majority of the upregulated miRNAs
are predicted to target and correlate in expression with
components of the mitochondrial complexes [13]. In the mouse
liver, several miRNAs found to be upregulated were associated
with targeting mRNAs important for detoxification and regener-
ation of the liver [11]. These findings point to the fact that
upregulation of specific miRNAs may target particular genes that
are important for tissue-specific aging decline. Interestingly, miR-
27a was found to be significantly upregulated in the Ames dwarf
mouse model of aging, which have extended lifespan [12].
Reduced expression of mir-27a was observed in control older
mice and was also found to be decreased in older individuals in our
miRNome analyses, suggesting that perhaps this miRNA may be
important for regulating longevity in both mice and humans and
may be an interesting miRNA to pursue in future studies.
It is interesting to note that a decrease in miRNA expression is
also observed during cellular senescence in human tissue culture
cells grown in vitro. Senescent cells accumulate with advancing age
in humans, primates and rodents, and are often found in tissues of
age-associated pathologies [15]. Furthermore, the data suggest
that senescent cells play a role in tumor suppression as well as a
potential, albeit controversial, role in contributing to the aging
process [15,31]. One characteristic of replicative senescence is a
decrease in protein translation. It is tempting to speculate that
decreased levels of miRNAs in older individuals, similar to
senescent cells, may help cells to maintain elevated protein levels at
a time when translation is depressed due to advancing age,
perhaps as an energy-saving or compensatory mechanism.
Several senescence-associated miRNAs and their targets have
been identified. In our studies, we found that several miRNAs
have similar expression patterns in both senescent cells and in
aging PBMCs, including miR-17, miR-24, miR-93, miR-141,
miR-146, miR-155 and miR-106a. However, several senescence-
associated miRNAs (miR-15b, miR-25, miR-106b) are either not
changed significantly or showed more interindividual variability in
our miRNome analysis, suggesting that some but not all miRNAs
expression patterns are consistent between senescent cells and
aged cells. This discrepancy could also be reflected in the different
cell types examined as it is known that some miRNAs show tissue
specificity. Based on our miRNome data, we further verified the
expression of miR-24 and miR-155 and showed that these
miRNAs are downregulated with age in our larger cohort
(Fig. 3). Intriguingly, it has been shown that miR-24 can target
E2F2, p16
INK4a, MKK4 and H2AX [17,19,29,32]. We found that
levels of H2AX mRNA and protein are higher in older individuals.
This finding is interesting because most studies have focused on
measuring the levels of c-H2AX, a posttranslational modification
of H2AX that marks DNA double-strand breaks [33]. It has been
reported that c-H2AX staining increases with age in human
PBMCs, in mouse tissues and with cellular senescence [30,34]. It is
interesting to propose that with increasing age miR-24 coordi-
nately modulates H2AX expression, in part to help to overcome
the additional oxidative stress and DNA damage that occurs with
age. Further studies will be needed to validate if increased
expression of H2AX is indeed a biomarker of age, in addition to,
c-H2AX.
Although we found that miR-155 decreased with age and others
have shown it decreased during cellular senescence [16], miR-155
is widely accepted as an oncogenic miRNA that has been found to
be upregulated in various cancers [4,35]. Because miR-155 is
localized to a fragile locus (termed the B cell integration cluster
BIC) that is an integration site of viral-induced lymphomas, it is
possible that expression of miR-155 is regulated differently from
other miRNAs. Consistent with this idea, expression of the BIC
itself does not always correlate with expression of miR-155 in
Hela cells were transfected with the dual-luciferase plasmids shown and either control siRNA, (Pre)miR-221 or (AS)miR-221. The ratio of the RL/FL
activity is shown. *P,0.05 using one-way ANOVA and Tukey’s post-hoc test for the indicated comparisons.
doi:10.1371/journal.pone.0010724.g005
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understand how levels of miR-155 are regulated.
In addition to the miR-155 oncomir, we found that several
other cancer-associated miRNAs are downregulated with age
including miR-103, miR-107, miR-128 and miR-221 (see Fig. 3C
for list of cancers associated with each miRNA). Although specific
miRNAs have been reported to be upregulated in cancer, most
miRNAs are generally downregulated in human tumors [37,38].
Global inhibition of miRNAs enhances both cellular transforma-
tion and tumorigenesis [39], further supporting a tumor-
promoting role for miRNA loss of function. In agreement of this
idea, expression of individual miRNAs repressed Myc-induced
tumorigenesis and viral introduction of let-7 suppressed tumor
growth in a mouse model of lung adenocarcinoma [40,41,42].
These studies underscore the importance of miRNA expression in
age-related diseases, such as cancer, and open the possibility that
miRNAs can be used for cancer therapeutics.
To determine if miRNAs would have therapeutic potential, it is
important to identify the targets for each miRNA. This is a
challenging task, since a single miRNA can regulate numerous
targets and a single gene can be targeted by multiple miRNAs. To
this end, we used Target Scan and Ingenuity Pathway Analysis to
decipher the predicted targets and pathways for the age-associated
oncomirs/ts-mirs identified in our study. Remarkably, only 2
targets overlapped between these miRNAs, NOVA1 and PIK3R1.
We focused on PIK3R1, which encodes the p85a subunit of PI3K,
a well-established integrator of multiple signaling pathways that
promote tumorigenesis. We found that suppression of the age-
associated miR-221 increases the abundance of p85 mRNA and
protein (Fig. 5). As changes in miR-221 expression have been
described in various cancers [4,35,43], and in the context of age in
this report, miR-221 may be a modulator of pathways important
for aging and tumorigenesis.
Interestingly, not only is PI3K important for human cancer but
is also part of the IGF-1 signaling pathway, which plays a well-
established role in longevity [2]. Moreover, mutations in the age-1
gene, which encodes a class 1 PI3K catalytic subunit, extends the
lifespan of C. elegans [44]. One caveat of the IGF-1 pathway is that
reduced signaling increases longevity, whereas, enhanced signaling
promotes cancer. It is possible that the aberrant expression of
different subunits of PI3K, as we have observed in this study, may
tip the balance to enhance or inhibit cancer progression during the
aging process. In support of this idea, upregulation of the PI3K
p110 subunit was recently reported in cancer stem cells and
activation of this pathway enhanced the tumorigenic potential of
these cells [45]. It would be interesting to examine if increased
levels of the PI3K p85 subunit are also observed in cancer stem
cells.
In addition to PI3K, we also examined expression of the miR-
221 target c-Kit in young and old individuals. Higher levels of c-
Kit protein were observed in older individuals, whereas, c-Kit
mRNA levels were unchanged between the age groups. These
data are consistent with a previous report that miR-221 primarily
regulates translation of c-Kit rather than c-Kit mRNA levels [26].
c-Kit is overexpressed and/or activated in various leukemias and
other cancers [27,28]. For example, it has been predicted that c-
Kit is expressed in 80–90% of acute myelogenous leukemia (AML)
cases and that coordinated activation of the c-Kit pathway and
other oncogenic signaling pathways contribute to the severity of
this cancer and other types of leukemias [27,28]. One interesting
observation is that PI3K is downstream of the c-Kit receptor
tyrosine kinase. Therefore, it is interesting to hypothesize that
upregulation of PI3K may help to potentiate c-Kit signaling in
hematopoietic cells with advancing age, and perhaps, this
enhanced signaling primes the cells for oncogenic transformation
[46].
Several of the age-associated miRNAs that we identified have
not been well-characterized including miR-130a, miR-496, and
miR-1538. Specifically, there are currently no published reports or
targets predicted yet in TargetScan or Pictar for miR-1538. In the
future, it will be interesting to examine how these underexplored
miRNAs contribute to the aging process.
Our cohort contains subjects of different races and sexes,
suggesting that downregulation of age-associated miRNAs may
occur regardless of both sex and race. Consistent with this idea,
three-way analysis of variance analysis using sex, race and age as
variables revealed that only miR-299-3p was significantly altered
in different sexes, expression is lower in males than females (data
not shown). Localized on chromosome 14q101, miR-299-3p was
recently proposed to be part of a miRNA signature that predicts
estrogen receptor expression in breast cancer patients, indicating
that this miRNA may play a role in hormonal regulation in normal
tissues and during oncogenesis [47].
In summary, we have identified several miRNAs that are
downregulated with human age. The loss of miRNA function
during the aging process may be due to transcriptional repression,
deletion, mutation, epigenetic silencing, or aberrant miRNA
processing [4,48]. Future work will determine how these age-
associated miRNAs decrease in abundance with age. Nevertheless,
it is important to determine the expression of miRNAs and their
targets with human age, as we have done here, and to follow-up
with a systematic analysis of the pathways regulated by each
miRNA in aging cells. A critical understanding of the precise role
each miRNA plays in the aging process will hopefully aid in the
development of new anti-aging therapies and in determining if
miRNAs and their targets could be used as diagnostic or
prognostic indicators of age or age-related diseases.
Materials and Methods
Study Participants
Fasting blood samples were obtained from participants in the
Healthy Aging in Neighborhoods of Diversity across the Life Span
(HANDLS) study of the National Institute on Aging Intramural
Research Program (NIA IRP). The purpose of this study is to
unravel the effects of race and socioeconomic status on the
development of age-associated health disparities. The cohort
consists of Whites and African Americans between the ages of 30–
64 residing in Baltimore, Maryland. The study has been approved
by the Institutional Review Board of the Med-Star Research
Institute and all participants provided written informed consent.
The demographics of the study sub-population presented in
Table 1 were collected from interviews and self-reported medical
history. For this cohort, we excluded participants with document-
ed Hepatitis B, Hepatitis C or human immunodeficiency virus
(HIV) infection.
Peripheral blood mononuclear cells (PBMCs) isolation
Blood samples collected in 8-ml VacutainerH heparinized vials
(BD, Franklin Lakes, NJ) were transported to the laboratory at
room temperature and peripheral blood mononuclear cell (PBMC)
isolation was performed within 3 hours of phlebotomy. Blood was
diluted with RPMI-1640 medium and Histopaque 1077 (Sigma-
Aldrich, St. Louis, MO) was added to the bottom of the tubes.
Samples were centrifuged at 200 x g for 15 min and the interphase
layer containing PBMCs were collected and furthered washed with
RPMI-1640 medium. The cell pellets were resuspended in
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DMSO, aliquoted and stored at 280uC.
Quantitative miRNome miRNA profiling
Cryopreserved PBMCs were thawed quickly in the presence of
0.2 ml PBS and RNaseOUT
TM (Invitrogen Carlsbad, CA) and
centrifuged at 1000 x g for three minutes. Total RNA was isolated
using TRIzolH (Invitrogen, Carlsbad, CA) and DNase treated
(Applied Biosystems, Foster City, CA) according to manufacturer’s
directions. RNA was quantified and assessed using both a
NanoDrop ND-1000 Spectrophotometer and the RNA 6000
Nano Total RNA Assay and Agilent Techonologies 2100
Bioanalyzer. We used the miRNome miRNA profiling kit from
System Biosciences (Mountain View, CA) to examine miRNA
expression in two young and two old participants (see Table 1 for
demographics) in two different experiments. Four micrograms of
RNA was reverse transcribed using QuantiMir
TM cDNA
techonology, which tags and converts small RNAs into cDNAs.
miRNA profiling was performed according to manufacturer’s
directions with some exceptions. In brief, 5 ml of Mastermix (all
the synthesized cDNA, SYBR Green master mix, Universal
Reverse Primer and nuclease free water) was added to a 96-well
plate containing 3 ml of the manufacturer’s human miRNA assay
primers (diluted 1:5). cDNA for one young and one old individual
were run on each plate on an Applied Biosystems 7500 Real-Time
PCR machine according to standard procedures. Samples were
normalized to U1 expression and analyzed using the DDCT
method. Similar results were observed with other normalization
genes.
Real-time RT-PCR
Total RNA from 14 young and 14 old subjects (see Table 1 for
demographics) were isolated and analyzed as above. cDNA was
synthesized using the QuantiMir
TM cDNA Kit (System Biosci-
ences, Mountain View, CA). Forward primers were designed to be
the exact sequences of the miRNAs listed in the miRBase database
(http://www.mirbase.org) and are listed in Table S4. An
Universal Reverse Primer was supplied by the manufacturer.
For gene expression analysis, gene-specific primer pairs for H2AX
were described previously [29] and other primers are as follows:
PI3K p85a subunit isoform 1 forward 59-AGCAACCTGGCA-
GAATTACGA and reverse 59- AAACGTGCACATCGAT-
CATTTC and for c-Kit 59-TTGTGATTTTGGTCTAGCCA-
GAGA and reverse 59-GTGCCATCCACTTCACAGGTAG.
Real-time RT-PCR reactions were performed according to the
manufacturer’s (System Biosciences, Mountain View, CA) direc-
tions on an Applied Biosystems 7500 Real-Time PCR System,
with the exception that 6 times more cDNA was needed to detect
c-Kit expression. miRNAs were normalized to the average of three
different miRNAs miR-147, miR-574-3p and miR-1469. The
expression of these miRNAs did not change in the two miRNome
analysis and also showed minimal variability in expression among
all the participants. Similar results were also obtained when we
normalized to the snoRNAs RNU24, RNU49 and U47. H2AX, c-
Kit and PI3K were normalized to the average of HPRT and UBC
expression, which were two reference genes that were found to be
the least variable reference genes in the participant PBMCs.
The TaqManH microRNA assay (Applied Biosystems) was used
to quantitate miR-24 and miR-221 expression in young and old
participants and normalized to miR-147 expression. For duplicate
wells, a total of 100 ng of RNA was used for miR-24 and miR-147
and 200 ng of RNA for miR-221.
Bioinformatics
Each age-associated miRNA was tested using Target Scan,
which uses a computational algorithm to identify predicted mRNA
targets. All the predicted targets from this analysis were then used
as input for Ingenuity Pathway Analysis. IPA scores the list of
genes for each miRNA against the canonical pathways in the
Ingenuity Knowledge Base Genes Only reference set and default
settings were used throughout the analysis. IPA has key
components for Signaling and Metabolic pathways analysis,
Cellular and Disease Process Analysis, Molecular Network
Analysis and Contextual Data analysis. For each analysis, IPA
ranks each function or pathway using the right-tailed Fisher Exact
Test, which measures the likelihood that the lists of genes are
associated with a certain pathway/function (www.ingenuity.com).
For each miRNA, the top rank for each analysis was used for
Table 2.
Immunoblotting of Protein Extracts from Patients
Cryopreserved PBMCs were thawed quickly, washed with cold
PBS and spun at 1000 x g for three minutes. Cell pellets were
resuspended in 2X Laemmli sample buffer, separated by SDS-
PAGE and probed by immunoblotting with anti-Histone H2AX
polyclonal antibodies (Millipore, Billerica, MA), p85a PI3K
monoclonal antibodies (BD Biosciences, San Jose, CA), and c-
Kit goat polyclonal antibodies (R&D systems, Minneapolis, MN).
Membranes were stripped and reprobed with anti-actin goat
polyclonal antibodies (Santa Cruz Biotechnology, Santa Cruz, CA)
and anti-Histone H3 antibodies (Millipore, Billerica, MA) as
protein loading controls. Immunoblots were quantified using
ImageJ.
Cell culture, transfection, and small RNAs
HeLa cells were cultured in DMEM containing 10% FBS and
transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA).
Anti-miR
TM miRNA inhibitor against miR-221 ((AS)miR-221) or
FAM
TM-labeled Anti-miR negative control (Ctrl siRNA) were
used at a final concentration of 100 nM (Ambion, Austin, TX).
RNA and protein were isolated from the cells forty eight hours
after transfection as described above.
Luciferase Assays
Plasmids for reporter analysis were generated from the dual-
luciferase reporter vector psiCHECK
TM-2 from Promega (re-
ferred to as pLuc). The p85a 39 UTR luciferase plasmids containing
predicted miR-221 sites (Fig. 5C) were generated by PCR using
the following primers: p85 (2644) F: CTCGAGgtttggtccagcctggttta
and R: GCGGCCGCcaaacttggcacttccttcc and p85 (4491) F:
CTCGAGctctcatcgccagacaactg and R: GCGGCCGCgcaacct-
caaagggaaaaatc (uppercase letters, Xho1 and Not1 sites). Hela
cells were transfected with 100 ng of the luciferase plasmids and
transfected 24 hrs later with 100 nM Ctrl siRNA, (AS)miR-221 or
(Pre)miR-221 (Ambion, Austin, TX). After 24 hrs, the ratio of RL
and FL activities were measured using the dual-luciferase kit
(Promega, Madison, WI) according to the manufacturer’s
instructions.
Supporting Information
Table S1 miRNome analysis of miRNA expression in young
versus old participants.
Found at: doi:10.1371/journal.pone.0010724.s001 (0.11 MB
XLS)
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downregulated miRNAs in the miRNome analysis.
Found at: doi:10.1371/journal.pone.0010724.s002 (0.04 MB
XLS)
Table S3 miRNome expression values for microRNAs exam-
ined in Fig. 3 and Fig. S1.
Found at: doi:10.1371/journal.pone.0010724.s003 (0.02 MB
XLS)
Table S4 Forward primer sequences for validated microRNAs.
Found at: doi:10.1371/journal.pone.0010724.s004 (0.05 MB
DOC)
Figure S1 Real-time RT-PCR results for changes in miRNA
expression in young and old participants. Expression of miRNAs
from the miRNome analysis were further validated in 14 young
and 14 old patient PBMCs (see Table 1B for detailed demographic
data) using real-time RT-PCR as described in Materials and
Methods. The histograms show normalized averages + SEM from
duplicate experiments. ##P=0.05 by Student’s t-test and
P=0.04 by three-way ANOVA, # P=0.08 by Student’s t-test.
Found at: doi:10.1371/journal.pone.0010724.s005 (3.73 MB TIF)
Figure S2 Lymphocyte marker expression in participant
PBMCs. CD4, CD8 and IL-7 receptor expression was examined
in young and old individuals using RT-qPCR and normalized to
the average of HPRT and UBC. The ratio of CD4/CD8
expression is also shown. The indicated P values show the
significance of each parameter between young and old individuals
using Student’s t-test.
Found at: doi:10.1371/journal.pone.0010724.s006 (1.23 MB TIF)
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